Cartography Biosciences

Executive Summary

Cartography Biosciences is a private biotechnology company pioneering a novel approach to cancer immunotherapy target discovery. Founded in 2021 and headquartered in San Francisco, the company leverages single-cell genomics, proteomics, and novel binder discovery to build a comprehensive antigen atlas. This atlas aims to identify safer and more effective targets for various therapeutic modalities, including antibodies, biologics, and cell & gene therapy. By focusing on precise targeting and minimizing toxic side effects, Cartography seeks to design broadly applicable immunotherapies. The company is currently in the Phase 1 stage, indicating early clinical development, and has raised undisclosed funding.

Upcoming Catalysts (preview)

• Q1 2027First Patient Dosed in Phase 1 Trial70% success
• Q4 2026IND Filing for Lead Program80% success
• Q2 2027Strategic Partnership Announcement50% success